Xellar Therapeutics, a cutting-edge technology company at the forefront of 'AI+Organ-on-a-Chip' innovation, has proudly declared the successful closure of its Series A funding round, amassing a substantial sum exceeding 200 million yuan. This pivotal financing round was solely spearheaded by China Life Equity, with ongoing support from existing investors. Established in late 2021 in Boston, USA, and headquartered in Beijing, China, Xellar Therapeutics is home to a team of exceptional talent. The company's proprietary OC-Plex next-generation tumor organ-on-a-chip platform seamlessly integrates 'digital staining' technology, presenting formidable industry barriers and delivering unparalleled predictive precision. Xellar Therapeutics has achieved remarkable strides in technological deployment and industry acclaim, forging strategic alliances with several top-tier global pharmaceutical entities and other key players. Additionally, the company has played a pivotal role in shaping the world's inaugural industry standard within the organ-on-a-chip domain. The capital raised from this financing endeavor will be predominantly allocated towards the construction of biointelligence infrastructure, expediting the development of its AI platform, and constructing a comprehensive 3D Bio Intelligence system.